ID: ALA2017008

Max Phase: Preclinical

Molecular Formula: C17H28N6O6S

Molecular Weight: 444.51

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCCCCCCNc1ncnc2c1ncn2[C@@H]1O[C@H](COS(N)(=O)=O)[C@@H](O)[C@H]1O

Standard InChI:  InChI=1S/C17H28N6O6S/c1-2-3-4-5-6-7-19-15-12-16(21-9-20-15)23(10-22-12)17-14(25)13(24)11(29-17)8-28-30(18,26)27/h9-11,13-14,17,24-25H,2-8H2,1H3,(H2,18,26,27)(H,19,20,21)/t11-,13-,14-,17-/m1/s1

Standard InChI Key:  WUNBYYXZRQCINK-LSCFUAHRSA-N

Associated Targets(Human)

SUMO-activating enzyme 861 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Ubiquitin-like modifier-activating enzyme 5 22 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

K562 73714 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 444.51Molecular Weight (Monoisotopic): 444.1791AlogP: 0.05#Rotatable Bonds: 11
Polar Surface Area: 174.71Molecular Species: NEUTRALHBA: 11HBD: 4
#RO5 Violations: 1HBA (Lipinski): 12HBD (Lipinski): 5#RO5 Violations (Lipinski): 1
CX Acidic pKa: 11.30CX Basic pKa: 3.76CX LogP: 0.35CX LogD: 0.35
Aromatic Rings: 2Heavy Atoms: 30QED Weighted: 0.35Np Likeness Score: 0.39

References

1. Lukkarila JL, da Silva SR, Ali M, Shahani VM, Xu GW, Berman J, Roughton A, Dhe-Paganon S, Schimmer AD, Gunning PT..  (2011)  Identification of NAE Inhibitors Exhibiting Potent Activity in Leukemia Cells: Exploring the Structural Determinants of NAE Specificity.,  (8): [PMID:24900352] [10.1021/ml2000615]

Source